Question 1

Research Studies

Accepted Answer

Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., Van Wyk, P., Pham, K., & Bridon, D. P. (2005). Human Growth Hormone-Releasing Factor (HGRF)1–29-Albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a Long-Lasting GRF analog. Endocrinology, 146(7), 3052–3058. https://doi.org/10.1210/en.2004-1286
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and Insulin-Like growth Factor I secretion by CJC-1295, a Long-Acting analog of GH-Releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism/Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
Ionescu, M., & Frohman, L. A. (2006). Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. The Journal of Clinical Endocrinology and Metabolism/Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. https://doi.org/10.1210/jc.2006-1702
Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471–477. https://doi.org/10.1016/j.ghir.2009.03.001
Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Endocrinology and Metabolism/American Journal of Physiology: Endocrinology and Metabolism, 291(6), E1290–E1294. https://doi.org/10.1152/ajpendo.00201.2006

Question 2

References

Accepted Answer

Abla, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290–E1294. https://doi.org/10.1152/ajpendo.00201.2006

Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF 1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in
normal adult subjects. Growth Hormone & IGF Research, 19(6), 471–477. https://doi.org/10.1016/j.ghir.2009.03.001

Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536

Heat Up Your Research! Use Code JULY20 for 20% Off

Information for CJC 1295 w DAC

Research Certificates of Analysis

GMP Certificates of Analysis

CJC 1295 w DAC Peptide Structure

Product Usage

Related Products

PCL Tirzepatide 60mg

Provider GMP PCL Semaglutide 10mg

Provider GMP PCL BPC-157 10mg

Provider GMP PCL MOTs C 10mg

Provider GMP PCL CJC 1295 w DAC 5mg

Provider GMP PCL Ipamorelin 5mg

Provider GMP PCL Retatrutide 10mg

Provider GMP PCL TB-500 5mg

Provider GMP PCL Tesamorelin 20mg

Provider GMP PCL Cagrilintide 10mg

Get In Touch!

Additional Resources

About PekCura